



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

NIVolumab / IPILImumab (Melanoma & RCC)



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): First or subsequent line therapy of unresectable or metastatic melanoma.
 Metastatic renal cell carcinoma.

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC \geq 1000; HB \geq 80; Plt \geq 100,000; CrCl $>$ 45 ml/min.

Pre-treatment Medications: (30-60 min before starting treatment)

Chlorphenamine 10 mg PO/IV

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
NIVolumab	3 mg/kg	IV in 100 mL NS over 60 min.	D1
IPILImumab	1 mg/kg	IV in 100 mL NS over 60 min.	D1
To be repeated every 3 weeks for 4 cycles, then NIVolumab 240mg IV every 2 weeks.			

Treatment Description:

Cycle	Date	NIVolumab	IPILImumab	Physician	Consultant
C# __					
C# __					
C# __					
C# __					

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for \geq 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No